People · Operator
Named in public records as an officer, director or promoter · active 2019–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ventus Therapeutics U.S., Inc. | — | Biotechnology | Series C | $186.8M | $1.6B | 2019 |
| Santa Ana Bio, Inc. | — | Biotechnology | Series B | $63.3M | $150.6M | 2023 |
Brendan Bulik-Sullivan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brendan Bulik-Sullivan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jerel Davis | 2 | 13 |
| Josh Resnick | 1 | 7 |
| Thomas Woiwode | 1 | 7 |
| Hao Wu | 1 | 5 |
| John Cassidy | 1 | 3 |
| Markus Warmuth | 1 | 3 |
| Jane Pritchett Henderson | 1 | 3 |
| Steven James | 1 | 3 |
| Shinichiro Fuse | 1 | 2 |
| Peter Emtage | 1 | 2 |
| Daniel Koerwer | 1 | 2 |
| Zachary McNealy | 1 | 1 |
| Mittie Doyle | 1 | 1 |
| Christine Borowski | 1 | 1 |
| Marcelo Bigalo | 1 | 1 |
| Michael Crackower | 1 | 1 |
| Marcelo Bigal | 1 | 1 |
| Dolca Thomas | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.